CRISM Therapeutics Corporation has attracted renewed attention on18 August 2026, withLSE:CRTX rising 6.98%.
Proteome Sciences plc has emerged as one of the notable UK healthcare movers on18 August 2026, withLSE:PRM gaining 11.42%.
Cambridge Cognition spent the summer of 2026 telling a turnaround story: double-digit revenue growth, a debt-freeBalance Sheetand a push into consumer brain health. Yet the shares have drifted lower again, a reminder that on AIM a good narrative and a fragile micro-cap valuation can …
Shares in the light-activated infection specialist have slipped again as investors count down to a make-or-break Phase 3 readout — with a thinning cash runway and no fresh catalyst to steady nerves. For a stock that has swung between 7.5p and 18.5p over the …
A microbiome pioneer that once traded above 22p is now nursing a share price in single digits, a former chief executive accused of fabricating revenue, and a set of half-year accounts that had to be restated. For a company built on the science of …
Fusion Antibodies, the Belfast-based antibody engineering specialist, has spent 2026 stitching together contract wins, patent grants and a proprietary discovery platform it hopes will reshape its economics. Yet the shares slipped again in mid-August, a reminder that on AIM a thin,Illiquidmicro-cap can drift lower …
MedPal AI has been one of London’s more eye-catching micro-cap stories of 2026, building a digital-health and pharmacyBusinessfrom a standing start into an £8.6m annualised revenue run rate in barely nine months. A modest dip of around 3.3% in a single session has prompted …
Optima Health has been one of the AIM market’s more talked-about small-caps this year, transformed by a £100m acquisition that made it Britain’s clear leader in occupational health. With full-year results due within days, a modest slide in the shares raises a fair question: …
After a bruising 2025 that stripped hVIVO of its record margins, the market wants proof that the recovery is real. A first-half update showing lower revenue but a doubled order book has left investors torn between a promising 2026-2028 pipeline and the near-term reality …
OptiBiotix has spent a decade promising that microbes can reshape how the world manages weight, cholesterol and gut health. With the shares slipping again in a quiet mid-August market, investors are asking whether the commercial turnaround finally taking shape is enough to rekindle a …